Insurer Bargaining and Negotiated Drug Prices in Medicare Part D

A controversial feature of Medicare Part D is its reliance on private insurers to negotiate drug prices and rebates with retail pharmacies and drug manufacturers. Central to this controversy is whether increases in market power--an undesirable feature in most settings--confer benefits in health

联邦医疗保险D部分（Medicare Part D）一项颇具争议的特征，在于其依托私人保险公司与零售药房及药品制造商协商药品价格与返利条款。该争议的核心在于，市场势力的增强——这在多数场景下均为负面属性——是否会为医疗健康领域带来益处。

搜集汇总

背景与挑战

背景概述

该数据集基于一篇NBER工作论文，研究Medicare Part D计划中保险公司谈判能力对药品价格的影响。研究发现，保险公司参保人数增加会显著降低谈判的药品价格和药房利润，尤其在有治疗替代品的药物中效果明显，且节约的成本可能转化为更低的保费。